AZD8926

TargetMol
Product Code: TAR-T30266
Supplier: TargetMol
CodeSizePrice
TAR-T30266-5mg5mg£1,091.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30266-50mg50mg£2,143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30266-100mg100mg£2,801.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
AZD8926 is a potent and selective inhibitor of GSK3β(glycogen synthase kinase-3β). AZD8926 is potential for treating Alzheimer?s disease (AD), schizophrenia, and chronic as well as acute neurodegenerative diseases.
CAS:
933785-68-3
Formula:
C25H27F4N7O2
Molecular Weight:
533.532
Purity:
0.98
SMILES:
CN1CCN(CC1)C(=O)c1ccc(Nc2ncc(F)c(n2)-c2cnc(n2C2CCOCC2)C(F)(F)F)cc1

References

1. A Novel Scalable Process to the GSK3? Inhibitor AZD8926 Based on a Heterocyclic Ziegler Coupling By Witt, Anette; Teodorovic, Peter; Linderberg, Mats; Johansson, Peter; Minidis, Anna From Organic Process Research & Development (2013), 17(4), 672-678. | Language: English, Database: CAPLUS 2. A new combination of (a) an ?-?4-??-?2-?neuronal nicotinic agonist and (b) a glycogen synthase kinase 3 (GSK3) inhibitor By Basun, Hans; Cox, Graham; Nordgren, Ingrid; Bencherif, Merouane From PCT Int. Appl. (2009), WO 2009017455 A1 20090205. | Language: English, Database: CAPLUS 3. New therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958 By Basun, Hans; Cox, Graham; Nordgren, Ingrid From PCT Int. Appl. (2009), WO 2009017453 A1 20090205. | Language: English, Database: CAPLUS 4. New therapeutic combination of a glycogen synthase kinase-?3 (GSK3) inhibitor and an ?7-?nicotinic agonist By Basun, Hans; Cox, Graham; Nordgren, Ingrid rom PCT Int. Appl. (2009), WO 2009017454 A1 20090205. | Language: English, Database: CAPLUS